The prevalence of diabetes mellitus and abnormal lipid status among Croatian hospitalized coronary heart disease patients [Prevalencija šećerne bolesti i poremećenih vrijednosti lipidograma u hospitaliziranih koronarnih bolesnika u Hrvatskoj] by Vražić, Hrvoje et al.
Coll. Antropol. 36 (2012) Suppl. 1: 223–228
Original scientific paper
The Prevalence of Diabetes Mellitus and Abnormal
Lipid Status among Croatian Hospitalized
Coronary Heart Disease Patients
Hrvoje Vra`i}1, Tomo Lucijani}1,2, Jozica [iki}1,3, Ivana Raj~an [poljari}1, Stojan Poli}4,
\ivo Ljubi~i}5, Katarina Mati}2, Ton}i Bo`in2, Irena [ubjak2 and Mijo Bergovec1,2
1 University of Zagreb, Dubrava University Hospital, Department of Internal Medicine, Division of Cardiology, Zagreb, Croatia
2 University of Zagreb, School of Medicine, Zagreb, Croatia
3 University of Zagreb, Sveti Duh University Hospital, Department of Internal Medicine, Division of Cardiology, Zagreb, Croatia
4 University of Split, Split University Hospital Centre, Department of Internal Medicine, Division of Cardiology, Split, Croatia
5 University of Zagreb, Dubrava University Hospital, Department of Internal Medicine, Zagreb, Croatia
A B S T R A C T
The aim of this article was to investigate the prevalence of diabetes mellitus and abnormal lipid status with selected
anthropometric variables in a sample of hospitalized coronary heart disease (CHD) patients in Croatia (N=1,298). Prev-
alence of diabetes mellitus was 31.6% (statistically significantly more frequent in women, 35.7% vs. 30.0%), while pre-
valences of increased total cholesterol were 72.0%, decreased HDL-cholesterol 42.6% (statistically significantly more fre-
quent in women, 50.2% vs. 39.6%), increased LDL-cholesterol 72.3% and increased triglycerides 51.5%. Reported data
on prevalences of diabetes mellitus can be somewhat reassuring (a decrease in its prevalence compared to data from
2006, but they still signal a situation which is a lot worse than in 2002 and 2003); the trend of rising prevalences of
dyslipidaemic cardiovascular risk factors must be a cause for an alarm, furthermore as today’s preventive and treatment
measures in cardiology, both primary and secondary, are strongly focused on dyslipidaemias.
Key words: coronary heart disease, type 2 diabetes mellitus, total cholesterol, LDL-cholesterol, HDL-cholesterol, tri-
glycerides
Introduction
Type 2 diabetes mellitus is recognized today as one of
main public health problems in the world1. The role of
type 2 diabetes mellitus as one of principal risk factors
for the development of cardiovascular disease (CVD) is
well investigated2. It’s continuously rising incidence and
prevalence is continually in the focus of attention and it
seems to be closely related with western dietary habits,
physical inactivity and ever more prevalent obesity. It is
well known that, apart from genetic and environmental
factors, its development and progression is also influ-
enced by lifestyle, habits and some individual factors, as
this has especially profoundly been investigated in type 2
diabetes mellitus3. On the other hand, it is encouraging
that change of lifestyle and habits can help prevent oc-
currence of diabetes mellitus, in this context body weight
reduction is considered as the main predictor of success
in this process4. Several studies have shown that in per-
sons with high risk for development of diabetes mellitus it
is possible to reduce its incidence through change of life-
style and habits, mainly with significant reduction of body
weight5–8, but, as seen in a study from India, even if no sig-
nificant weight reduction is achieved9. European Society
of Cardiology (ESC) 2007 Guidelines on management of
diabetes mellitus and CVD prevention give recommenda-
tions on desired goals in patients with coronary heart dis-
ease (CHD) and diabetes mellitus10–13, whereas the ESC
Guidelines from 2008 give recommendations on desired
goals in patients that have had myocardial infarction14.
Lipidogram analysis usually involves measurement of
four components: total cholesterol, LDL-cholesterol, HDL-
-cholesterol and triglycerides. Measured levels of all men-
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tioned components if they are increased are considered
as risk factors, except in case of HDL-cholesterol, where
its decreased measured levels are considered as a risk
factor. 2007 ESC Guidelines give recommendations on fa-
vourable lipidogram values both for primary and second-
ary prevention10–13, while ESC Guidelines from 2008 give
recommendations on desired lipidogram target values in
patients that have suffered from a myocardial infarction
with ST-segment elevation14. Published data in global lit-
erature has shown that all four lipidogram components
are some of principal risk factors for the development of
CVD – increased total cholesterol15,16, increased LDL-
-cholesterol, decreased HDL-cholesterol17 and increased
triglyceride levels17.
Materials and Methods
The survey included 1,298 patients hospitalized be-
tween October 1st 2007 and January 7th 2010 for acute or
chronic CHD in various hospitals in Croatia. It was per-
formed in the above mentioned period in Dubrava Uni-
versity Hospital (Zagreb), Sveti Duh University Hospital
(Zagreb), Bjelovar General Hospital, ^akovec General
Hospital, Karlovac General Hospital, Koprivnica General
Hospital, Slavonski Brod General Hospital, Vara`din Ge-
neral Hospital, Rijeka University Hospital Centre, Pula
General Hospital, Split University Hospital Centre, Du-
brovnik General Hospital and Zadar General Hospital.
A special questionnaire was produced for this study
which allowed recording of required data. Questionnaire
was made after series of consultations with experts and
literature and it was compiled by model of large clinical
trials conducted in Europe and Croatia [INTERHEART18,
EUROASPIRE (European action on secondary preven-
tion by intervention to reduce events) I19 and II20, EH-
-UH (Epidemiology of hypertension in Croatia)21, TASPIC-
-CRO (Treatment and secondary prevention of ischemic
coronary events in Croatia)22]. This allowed the investi-
gators to be able to efficiently compare results. Most of
the questions had multiple answers offered in advance to
acquire greater accuracy. Data was collected on patient
history (personal and family history), age, sex and infor-
mation on cardiovascular risk factors and discharge diag-
noses. Physical examination was performed and its find-
ings were recorded. Special focus in the questionnaire
was on diabetes mellitus and dyslipidaemia. It was possi-
ble to measure the presence of these risk factors as the
following laboratory data was recorded in the question-
naire: blood glucose levels with information on duration
of fasting and previously diagnosed diabetes mellitus and
lipidogram with values of total cholesterol, LDL-choles-
terol, HDL-cholesterol and triglycerides.
Categories used in recording of presence of diabetes
mellitus included: normal blood glucose levels, glucose
intolerance and diabetes mellitus – as defined according
to World Health Organization (WHO) 1999 Guidelines.
Glucose concentrations lower than 6.1 mmol/L after fast-
ing, or 7.8 mmol/L after meal were considered as normal.
Glucose concentrations between 6.1 mmol/L and 7 mmol/L
after fasting and between 7.8 mmol/L and 11 mmol/L af-
ter meal were considered as indicative of glucose intoler-
ance. Values of glucose concentrations higher than 7
mmol/L after fasting, or 11.1 mmol/L after meal were
considered as indicative of diabetes mellitus12,13,23. Pa-
tients with previously diagnosed diabetes mellitus were
considered as having diabetes mellitus regardless of re-
corded glucose concentrations.
Presence of dyslipidaemia was defined according to
currently valid Guidelines10,11,13,14: in patients which we-
re already taking statins, or as presence of LDL choles-
terol concentration equal to or higher than 2.5 mmol/L in
morning blood sample after period of 12 hours with no
food intake, or as total cholesterol concentration equal to
or higher than 4.5 mmol/L. Triglyceride concentration
equal to or higher than 1.7 mmol/L and HDL cholesterol
concentration less than 1 mmol/L in men and 1.2 mmol/L
in women were considered as markers of increased car-
diovascular risk.
Data were collected by physicians or trained person-
nel (nurse), coded and entered into the electronic file.
Confidentiality of data was ensured in accordance with
current applicable codes, declarations and other provi-
sions. The results are shown in tables, and for quantita-
tive variables descriptive statistics were done with ap-
propriate measures of central tendency and variability
(mean, standard deviation, medians, associated inter-
quartile ranges). Normal distribution of quantitative va-
riables was tested by Kolmogorov-Smirnov test, and then
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TABLE 1
DISTRIBUTION OF SELECTED LABORATORY AND ANTHROPOMETRIC VARIABLES IN SUBJECTS
Selected variables
N Mean SD Min.
Percentiles
Max.
25. 50. (Median) 75.
Serum glucose (mmol/L) 1220 7.42 3.49 0.50 5.56 6.40 8.00 53.00
Serum total cholesterol (mmol/L) 1177 5.37 1.40 1.59 4.40 5.30 6.20 15.21
Serum HDL-cholesterol (mmol/L) 1088 1.22 0.49 0.43 0.96 1.14 1.39 8.30
Serum LDL-cholesterol (mmol/L) 1059 3.30 1.14 0.42 2.43 3.24 4.00 8.80
Serum triglycerides (mmol/L) 1166 2.05 1.52 0.33 1.22 1.76 2.39 26.25
N – number, SD – standard deviation, Min. – minimum, Max. – maximum, mmol/L – millimoles per litre, HDL – high density lipopro-
tein, LDL – low density lipoprotein
appropriate parametric (t-test for independent samples
and analysis of variance – ANOVA) or nonparametric
tests (Mann-Whitney U test, Kruskal-Wallis test) were
used. The c2 test was also used.
Statistically significant results were considered those
with p values <0.05. Statistical analysis was made using
the software PASW version 17.02 (Chicago Inc., IL, www.
spss.com).
Results
Table 1 shows the distribution of measured laboratory
and anthropometric variables in the whole sample. Mean
serum glucose levels were 7.42±3.49 mmol/L, mean se-
rum total cholesterol levels were 5.37±1.40 mmol/L, mean
serum HDL-cholesterol levels were 1.22±0.49 mmol/L,
mean serumLDL-cholesterol levels were 3.30±1.14mmol/L
and mean serum triglyceride levels were 2.05±1.52
mmol/L. Comparison of these variables by sex is shown
in Table 2. Only statistically significant difference was
found in serum levels of HDL-cholesterol: in women its
level was higher than in men (1.28±0.45 mmol/L vs.
1.19±0.50 mmol/L, Table 2, p<0.001, Mann Whitney U
test).
Subjects were divided into 3 groups depending on
measured serum glucose levels (measured in mmol/L)
based on the data from the current Guidelines, taking
into account whether or not they were fasting at the time
when the sample was taken. Normal serum glucose lev-
els (<6.1 fasting or <7.8 after meal) were recorded in 388
subjects (46.1%), glucose intolerance (6.1–7 fasting or
7.8–11.1 after meal) was recorded in 188 subjects (22.3%)
and diabetes mellitus (>7 fasting or >11.1 after meal)
was recorded in 266 subjects (31.6%). The data on serum
glucose level was not available for 456 subjects. Table 3
shows comparison of measured serum glucose levels by
sex. Diabetes mellitus was statistically significantly more
frequent in women (35.7% vs. 30.0%), and glucose intol-
erance was statistically significantly more frequent in
men (24.5% vs. 16.8%, p=0.040, c2-test).
Subjects were also divided into two groups according
to the serum total cholesterol levels as recommended by
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TABLE 2
SELECTED LABORATORY AND ANTHROPOMETRIC VARIABLES IN SUBJECTS BY SEX
Selected variables Sex N Mean SD Min.
Percentiles
Max. p
25. 50. (Median) 75.
Serum glucose (mmol/L)
Men 864 7,29 3.21 3.40 5.50 6.40 7.80 32.50
0.099
Women 356 7.73 4.06 0.50 5.59 6.51 8.60 53.00
Serum total cholesterol (mmol/L)
Men 836 5.34 1.35 1.59 4.40 5.28 6.16 11.04
0.367
Women 341 5.45 1.49 1.80 4.39 5.37 6.20 15.21
Serum HDL-cholesterol (mmol/L)
Men 771 1.19 0.50 0.43 0.93 1.10 1.34 8.30
<0.001
Women 317 1.28 0.45 0.47 1.01 1.20 1.46 6.41
Serum LDL-cholesterol (mmol/L)
Men 754 3.30 1.13 0.42 2.45 3.25 3.99 8.80
0.800
Women 305 3.30 1.18 0.79 2.41 3.20 4.05 8.57
Serum triglycerides (mmol/L)
Men 832 2.09 1.62 0.40 1.23 1.77 2.40 26.25
0.251
Women 334 1.95 1.20 0.33 1.20 1.64 2.30 11.75
Mann-Whitney U test was used, p<0.05 is considered statistically significant
N – number, SD – standard deviation, Min. – minimum, Max. – maximum, mmol/L – millimoles per litre, HDL – high density lipopro-
tein, LDL – low density lipoprotein
TABLE 3
COMPARISON OF SERUM GLUCOSE CONCENTRATIONS BY SEX
Sex
Serum glucose concentrations in mmol/L (groups)
TotalNormal levels (<6.1 fasting
or <7.8 after meal)
Glucose intolerance (6.1–7 fasting
or 7.8–11.1 after meal)
Diabetes mellitus (>7 fasting
or >11.1 after meal)
Male 275 (45.5%) 148 (24.5%) 181 (30.0%) 604 (100.0%)
Female 113 (47.5%) 40 (16.8%) 85 (35.7%) 238 (100.0%)
Total 388 (46.1%) 188 (22.3%) 266 (31.6%) 842 (100.0%)
c2=6.455; df=2; p=0.040
c2 test was used, p<0.05 is considered statistically significant
mmol/L – millimoles per litre, % – percent, df – degrees of freedom
the Guidelines. One group consisted of subjects with to-
tal cholesterol levels <4.5 mmol/L (330 subjects, 28.0%)
and the other group consisted of subjects with total cho-
lesterol levels 4.5 mmol/L (847 subjects, 72.0%), while
the data was not available for 121 subjects. Comparison
of serum total cholesterol levels by sex showed no statis-
tically significant differences (Table 4). It is worth men-
tioning, however, that in both groups more than 70% of
subjects have serum total cholesterol values above those
which are recommended by the Guidelines.
Subjects were also divided into two groups in relation
to their serum HDL-cholesterol levels – one in which the
serum HDL-cholesterol was lower than recommended
levels (1 mmol/L in men and 1.2 mmol/L in women;
464 subjects, 42.6%) and the other one in which the se-
rum HDL-cholesterol was within the recommended ran-
ge (>1 mmol/L in men and >1.2 mmol/L in women, 624
subjects, 57.4%). The data was not available for 210 sub-
jects. Table 5 shows the comparison of serum HDL-cho-
lesterol values in subjects by sex – there were statistically
significantly more female subjects with serum HDL-cho-
lesterol levels below those which are recommended by
the Guidelines (50.2% vs. 39.6%, p=0.001, c2-test).
Subjects were also divided into two groups regarding
their serum LDL-cholesterol levels: 293 subjects (27.7%)
had those values within recommended range (<2.5
mmol/L), while in 766 subjects (72.3%) those levels were
above recommended range (2.5 mmol/L); finally, for 239
subjects the data were not available. There were no sta-
tistically significant differences between sexes (Table 6).
Finally, 565 subjects (48.5%) had serum triglyceride
levels within the recommended range (<1.7 mmol/L) and
601 (51.5%) subjects had those values above the recom-
mended range (1.7 mmol/L), the data was not available
for 132 subjects. There were no statistically significant
differences between sexes (Table 7).
Discussion
This article investigated prevalences of two well-known
cardiovascular risk factors – diabetes mellitus and dysli-
pidaemia (total cholesterol, HDL-cholesterol, LDL-cho-
lesterol and triglycerides) in the population of hospital-
ized Croatian CHD patients. As Croatia was one of the
countries which participated in the European action on
secondary prevention by intervention to reduce events
(EUROASPIRE) III study performed in 22 European
countries in 200624, it is possible to compare this data
with both Croatian and European data from that study.
Furthermore, valuable data on hospitalized Croatian CHD
patients was presented in Treatment and secondary pre-
vention of ischemic coronary events in Croatia (TASPIC-
-CRO) V study which was performed in Croatia in 2002
and 200322.
Diabetes mellitus has been shown to be one of major
risk factors for the development of CHD2 and is certainly
one of largest public health problems in the world today1.
In this study, 46.1% of subjects had normal serum glu-
cose levels, while 31.6% had diabetes mellitus (Table 3).
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TABLE 4




<4.5 mmol/L 4.5 mmol/L
Male 237 (28.3%) 599 (71.7%) 836 (100.0%)
Female 93 (27.3%) 248 (72.7%) 341 (100.0%)
Total 330 (28.0%) 847 (72.0%) 1177 (100.0%)
c2=0.139; df=1; p=0.709
c2-test was used, p<0.05 is considered statistically significant
mmol/L –millimoles per litre, % – percent, df – degrees of freedom
TABLE 5









Male 305 (39.6%) 466 (60.4%) 771 (100.0%)
Female 159 (50.2%) 158 (49.8%) 317 (100.0%)
Total 464 (42.6%) 624 (57.4%) 1088 (100.0%)
c2=10.317; df=1; p=0.001
c2-test was used, p<0.05 is considered statistically significant
mmol/L – millimoles per litre, HDL – high density lipoprotein, %
– percent, df – degrees of freedom, M – men, F – women
TABLE 6
SERUM LDL-CHOLESTEROL BY SEX
Sex LDL-cholesterol (groups)
Total
<2.5 mmol/L 2.5 mmol/L
Male 208 (27.6%) 546 (72.4%) 754 (100.0%)
Female 85 (27.9%) 220 (72.1%) 305 (100.0%)
Total 293 (27.7%) 766 (72.3%) 1059 (100.0%)
c2=0.009; df=1; p=0.926
c2-test was used, p<0.05 is considered statistically significant
mmol/L – millimoles per litre, LDL – low density lipoprotein, % –
percent, df – degrees of freedom
TABLE 7




<1.7 mmol/L 1.7 mmol/L
Male 393 (47.2%) 439 (52.8%) 832 (100.0%)
Female 172 (51.5%) 162 (48.5%) 334 (100.0%)
Total 565 (48.5%) 601 (51.5%) 1166 (100.0%)
c2=1.733; df=1; p=0.188
c2-test was used, p<0.05 is considered statistically significant
mmol/L –millimoles per litre, % – percent, df – degrees of freedom
While this finding does demonstrate a further increase in
comparison with the recorded prevalence of diabetes
mellitus in TASPIC-CRO V study (30%)22, it is still an
improvement when compared with the reported preva-
lence of diabetes mellitus in EUROASPIRE III study,
which reported prevalence of diabetes mellitus of 34.8%
in Europe and 35.3% in Croatia24. Statistically signifi-
cantly more women than men had diabetes mellitus
(35.7% vs. 30.0%, p=0.040, Table 3) and interestingly,
this statistically significant difference between sexes has
also been observed TASPIC-CRO V study (28% of men
and 34% of women had diabetes)22.
Assessment of the level of influence of a dyslipidaemia
usually involves analysis of four main lipidogram compo-
nents: total cholesterol, LDL-cholesterol, HDL-choles-
terol and triglycerides. Levels above those recommended
by the Guidelines for total cholesterol, LDL-cholesterol
and triglycerides represent a cardiovascular risk factor,
while levels of HDL-cholesterol below those recommen-
ded by the Guidelines also represent an established car-
diovascular risk factor15–17.
Unfortunately, as much as 72.0% of subjects in this
study had total cholesterol levels higher than those rec-
ommended by current ESC Guidelines. This represents
further increase in prevalence of this risk factor, as it’s
prevalence in TASPIC-CRO V study was 69%22 and in
EUROASPIRE III study considerably less (52%)24. Al-
though there were no statistically significant differences
between sexes, this represents a change, as in TASPIC-
-CRO V study the total cholesterol above recommended
levels was recorded more frequently in women than in
men22.
Levels of HDL-cholesterol which were too low accord-
ing to the current Guidelines were found in 42.6% of sub-
jects, and this was more frequently the case in women
(Table 5, 50.2% vs. 39.6%). When these data are com-
pared to both other relevant studies, one can see that the
prevalence of this risk factor is increasing. In EURO-
ASPIRE III study the prevalence was 36.7% in Europe
and 34.1% in Croatia24; while in TASPIC-CRO V study it
was 42%22. Contrary to results from our study, in TASPIC-
-CRO V study values of HDL-cholesterol lower than
those recommended by the guidelines were more fre-
quently present in men22.
A similar result was found when the data on preva-
lence of raised LDL-cholesterol was analysed – as much
as 72.3% of subjects were in this group. This again repre-
sents a further increase in prevalence (in TASPIC-CRO
V study the prevalence was 69%)22. There were no statis-
tically significant differences between sexes in preva-
lence of this risk factor, however, it was, like for total cho-
lesterol, reported in TASPIC-CRO V study that this risk
factor was more frequently present in women22. One
could speculate that the difference between sexes had
been annulated by higher increase in prevalence of in-
creased total cholesterol and LDL-cholesterol in men
than in women.
More than half of the subjects (51.5%) had trigly-
ceride levels higher than those recommended by the
Guidelines, while there were no statistically significant
differences between sexes. Knowing that in TASPIC-
-CRO V study only 37% of subjects had this risk factor22
and in EUROASPIRE III it was present in 49.9% of sub-
jects in Croatia (it was 51.5% on the level of European
sample)24, one can see a clear rise in it prevalence. This is
an alarming sign, as it means that we are closer than
ever to the European prevalences.
Reported data on prevalences of diabetes mellitus can
be somewhat reassuring (as they represent a decrease in
its prevalence compared to data from 2006, but they still
signal a situation which is a lot worse than in 2002 and
2003); the trend of rising prevalences of dyslipidaemic
cardiovascular risk factors must be a cause for an alarm,
furthermore as today’s preventive and treatment mea-
sures in cardiology, both primary and secondary, are
strongly focused on dyslipidaemias. One would expect
that with ever-increasing use of drugs and other inter-
ventions, those prevalences would show a stable decreas-
ing trend. However, our data suggests this is still not the
case. One can only speculate what those prevalences
would be like if our society was not combating these risk
factors at all.
Acknowledgements
This study was supported by the Ministry of Science,
Education and Sports of the Republic of Croatia, project
number 108-1080135-126 (Risk factors by region in hos-
pitalised coronary heart disease patients, led by prof.
Mijo Bergovec) which is a part of a programme of projects
number 1080135 (Regionalism, dynamics of cardiovascu-
lar risk factors and health interventions, led by prof. Mijo
Bergovec).
R E F E R E N C E S
1. KING H, AUBERT RE, HERMAN WH, Diabetes Care, 21 (1998)
1414. — 2. PYORALA K, LAAKSO M, UUSITUPA M, Diabetes Metab
Rev, 3 (1987) 463. — 3. MENSINK M, CORPELEIJN E, FESKENS EJ,
KRUIJSHOOPM, SARIS WH, DE BRUIN TW, BLAAK EE, Diabetes Res
Clin Pract, 61 (2003) 49. — 4. AMERICAN DIABETES ASSOCIATION,
BANTLE JP, WYLIE-ROSETT J, ALBRIGHT AL, APOVIAN CM,
CLARK NG, FRANZ MJ, HOOGWERF BJ, LICHTENSTEIN AH,
MAYER-DAVIS E, MOORADIAN AD, WHEELER ML, Diabetes Care, 31
Suppl 1 (2008) S61. — 5. PAN XR, LI GW, HU YH, WANG JX, YANGWY,
AN ZX, HU ZX, LIN J, XIAO JZ, CAO HB, LIU PA, JIANG XG, JIANG
YY, WANG JP, ZHENGH, ZHANGH, BENNETT PH, HOWARD BV, Dia-
betes Care, 20 (1997) 537. — 6. TUOMILEHTO J, LINDSTRÖM J, ERIK-
SSON JG, VALLE TT, HÄMÄLÄINENH, ILANNE-PARIKKA P, KEINÄ-
NEN-KIUKAANNIEMI S, LAAKSO M, LOUHERANTA A, RASTAS M,
SALMINEN V, UUSITUPA M, FINNISH DIABETES PREVENTION
STUDY GROUP, N Engl J Med, 344 (2001) 1343. — 7. KOSAKA K,
NODA M, KUZUYA T, Diabetes Res Clin Pract, 67 (2005) 152. — 8.
KNOWLER WC, BARRETT-CONNOR E, FOWLER SE, HAMMAN RF,
H. Vra`i} et al.: Diabetes and Lipids in CHD Patients, Coll. Antropol. 36 (2012) Suppl. 1: 223–228
227
LACHIN JM, WALKER EA, NATHAN DM, DIABETES PREVENTION
PROGRAM RESEARCH GROUP, N Engl J Med, 346 (2002) 393. — 9.
RAMACHANDRAN A, SNEHALATHA C, MARY S, MUKESH B, BHA-
SKAR AD, VIJAY V, INDIAN DIABETES PREVENTION PROGRAMME
(IDPP), Diabetologia, 49 (2006) 289. — 10. GRAHAM I, ATAR D, BOR-
CH-JOHNSEN K, BOYSEN G, BURELL G, CIFKOVA R, DALLONGE-
VILLE J, DE BACKER G, EBRAHIM S, GJELSVIK B, HERRMANN-
-LINGEN C, HOES A, HUMPHRIES S, KNAPTONM, PERK J, PRIORI
SG, PYORALA K, REINER Z, RUILOPE L, SANS-MENENDEZ S,
SCHOLTE OP REIMER W, WEISSBERG P, WOOD D, YARNELL J,
ZAMORANO JL, WALMA E, FITZGERALD T, COONEY MT, DUDINA
A, EUROPEAN SOCIETY OF CARDIOLOGY (ESC) COMMITTEE FOR
PRACTICE GUIDELINES (CPG), Eur Heart J, 28 (2007) 2375. — 11.
GRAHAM I, ATAR D, BORCH-JOHNSEN K, BOYSEN G, BURELL G,
CIFKOVA R, DALLONGEVILLE J, DE BACKER G, EBRAHIM S, GJEL-
SVIK B, HERRMANN-LINGENC, HOES A, HUMPHRIES S, KNAPTON
M, PERK J, PRIORI SG, PYORALA K, REINER Z, RUILOPE L, SANS-
-MENENDEZ S, OP REIMER WS, WEISSBERG P, WOOD D, YARNELL
J, ZAMORANO JL, WALMA E, FITZGERALD T, COONEY MT, DUDI-
NA A, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, DICKSTEIN
K, FUNCK-BRENTANO C, FILIPPATOS G, HELLEMANS I, KRISTEN-
SEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WI-
DIMSKY P, ZAMORANO JL, ALTINER A, BONORA E, DURRINGTON
PN, FAGARD R, GIAMPAOLI S, HEMINGWAY H, HAKANSSON J,
KJELDSEN SE, LARSEN L, MANCIA G, MANOLIS AJ, ORTH-GOMER
K, PEDERSEN T, RAYNER M, RYDEN L, SAMMUT M, SCHNEIDER-
MAN N, STALENHOEF AF, TOKGÖZOGLU L, WIKLUND O, ZAMPE-
LAS A, EUROPEAN SOCIETY OF CARDIOLOGY (ESC), EUROPEAN
ASSOCIATION FOR CARDIOVASCULAR PREVENTION AND REHA-
BILITATION (EACPR), COUNCIL ON CARDIOVASCULAR NURSING,
EUROPEAN ASSOCIATION FOR STUDY OF DIABETES (EASD), IN-
TERNATIONAL DIABETES FEDERATION EUROPE (IDF-EUROPE),
EUROPEAN STROKE INITIATIVE (EUSI), SOCIETY OF BEHAV-
IOURAL MEDICINE (ISBM), EUROPEAN SOCIETY OF HYPERTEN-
SION (ESH), WONCA EUROPE (EUROPEAN SOCIETY OF GENERAL
PRACTICE/FAMILY MEDICINE), EUROPEAN HEART NETWORK
(EHN), EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS), Eur J Car-
diovasc Prev Rehabil, 14 (2007) S1. — 12. GRUPODE TRABAJO SOBRE
DIABETES Y ENFERMEDADES CARDIOVASCULARES DE LA SO-
CIEDAD EUROPEA DE CARDIOLOGÍA Y DE LA SOCIEDAD EURO-
PEA PARA EL ESTUDIO DE LA DIABETES, RYDÉN L, STANDL E,
BARTNIK M, VAN DEN BERGHE G, BETTERIDGE J, DE BOER MJ,
COSENTINO F, JÖNSSON B, LAAKSO M, MALMBERG K, PRIORI S,
OSTERGREN J, TUOMILEHTO J, THRAINSDOTTIR I, Rev Esp Car-
diol, 60 (2007) 1e. — 13. RYDÉN L, STANDL E, BARTNIK M, VAN DEN
BERGHE G, BETTERIDGE J, DE BOER MJ, COSENTINO F, JÖNSSON
B, LAAKSO M, MALMBERG K, PRIORI S, OSTERGREN J, TUOMILE-
HTO J, THRAINSDOTTIR I, VANHOREBEEK I, STRAMBA-BADIALE
M, LINDGREN P, QIAO Q, PRIORI SG, BLANC JJ, BUDAJ A, CAMM J,
DEAN V, DECKERS J, DICKSTEINK, LEKAKIS J, MCGREGORK, ME-
TRAM, MORAIS J, OSTERSPEY A, TAMARGO J, ZAMORANO JL, DE-
CKERS JW, BERTRAND M, CHARBONNEL B, ERDMANN E, FERRA-
NNINI E, FLYVBJERG A, GOHLKE H, JUANATEY JR, GRAHAM I,
MONTEIRO PF, PARHOFER K, PYÖRÄLÄ K, RAZ I, SCHERNTHA-
NER G, VOLPE M, WOOD D, TASK FORCE ON DIABETES AND CAR-
DIOVASCULAR DISEASES OF THE EUROPEAN SOCIETY OF CAR-
DIOLOGY (ESC), EUROPEAN ASSOCIATION FOR THE STUDY OF
DIABETES (EASD), Eur Heart J, 28 (2007) 88. — 14. VAN DE WERF F,
BAX J, BETRIU A, BLOMSTROM-LUNDQVIST C, CREA F, FALK V,
FILIPPATOS G, FOX K, HUBER K, KASTRATI A, ROSENGREN A,
STEG PG, TUBARO M, VERHEUGT F, WEIDINGER F, WEIS M; ESC
COMMITTEE FOR PRACTICE GUIDELINES (CPG), Eur Heart J, 29
(2008) 2909. — 15. THE POOLING PROJECT RESEARCH GROUP, J
Chronic Dis, 31 (1978) 201. — 16. NEATON JD, BLACKBURN H, JA-
COBS D, KULLER L, LEE DJ, SHERWIN R, SHIH J, STAMLER J,
WENTWORTH D, Arch Intern Med, 152 (1992) 1490. — 17. HALL WH,
JAMA, 269 (1993) 505. — 18. YUSUF S, HAWKEN S, OUNPUU S, DANS
T, AVEZUM A, LANAS F, MCQUEEN M, BUDAJ A, PAIS P, VARIGOS J,
LISHENG L, INTERHEART STUDY INVESTIGATORS, Lancet, 364
(2004) 937. — 19. EUROASPIRE STUDY GROUP, Eur Heart J, 18 (1997)
1569. — 20. EUROASPIRE II STUDY GROUP, Eur Heart J, 22 (2001)
554. — 21. JELAKOVIC B, ZELJKOVIC-VRKIC T, PECIN I, DIKA Z, JO-
VANOVIC A, PODOBNIK D, SMUC T, GAMBERGER D, KATIC K, KAS-
NER M, KUZMANIC D; EH-UH ISTRAZIVACKE SKUPINE, Acta Med
Croatica, 61 (2007) 287. — 22. REINER Z, MIHATOV S, MILICIC D,
BERGOVEC M, PLANINC D, TASPIC-CRO STUDY GROUP INVESTI-
GATORS, Eur J Cardiovasc Prev Rehabil, 13 (2006) 646. — 23. CONSUL-
TATION WHO. Definition, diagnosis and classification of diabetes melli-
tus and its complications. Part 1: Diagnosis and classification of diabetes
mellitus (WHO, Geneva, 1981). — 24. KOTSEVA K, WOOD D, DE BA-
CKER G, DE BACQUER D, PYÖRÄLÄ K, KEIL U, EUROASPIRE
STUDY GROUP, Eur J Cardiovasc Prev Rehabil, 16 (2009) 121.
H. Vra`i}
University of Zagreb, Dubrava University Hospital, Department of Internal Medicine, Division of Cardiology,
Av. G. [u{ka 6, 10000 Zagreb, Croatia
e-mail: vrazic@gmail.com
PREVALENCIJA [E]ERNE BOLESTI I POREME]ENIH VRIJEDNOSTI LIPIDOGRAMA U
HOSPITALIZIRANIH KORONARNIH BOLESNIKA U HRVATSKOJ
S A @ E T A K
Cilj ovog rada bio je pokazati prevalenciju {e}erne bolesti i poreme}enih vrijednosti lipidograma uz izabrane antro-
pometrijske varijable na uzorku bolesnika hospitaliziranih zbog koronarne bolesti u Republici Hrvatskoj (N=1.298).
Prevalencija {e}erne bolesti iznosila je 31,6% (statisti~ki znatno ~e{}a u `ena, 35,7% prema 30,0%), dok su prevalencije
povi{enog ukupnog kolesterola iznosile 72,0%, smanjenog HDL-kolesterola 42,6% (statisti~ki znatno ~e{}i u `ena, 50,2%
prema 39,6%), povi{enog LDL-kolesterola 72,3% i povi{enih triglicerida 51,5%. Iako ovdje prikazani podaci vezani uz
u~estalost {e}erne bolesti mogu biti donekle ohrabruju}i (budu}i da pokazuju smanjenje prevalencije {e}erne bolesti u
usporedbi sa podacima iz 2006. g., no svejedno pokazuju puno goru situaciju u odnosu na onu iz 2002. i 2003. g.); trend
rastu}ih prevalencija dislipidemijskih kardiovaskularnih ~imbenika rizika mora biti znakom za uzbunu, tim vi{e jer su
dana{nje mjere prevencije i lije~enja, primarne i sekundarne, sna`no usredoto~ene na dislipidemije.
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